Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

108.06
-0.0800-0.07%
Post-market: 108.060.00000.00%19:30 EDT
Volume:272.52K
Turnover:29.38M
Market Cap:1.01B
PE:87.56
High:108.33
Open:108.14
Low:107.29
Close:108.14
52wk High:118.00
52wk Low:90.60
Shares:9.39M
Float Shares:9.39M
Volume Ratio:0.61
T/O Rate:2.90%
Dividend:2.18
Dividend Rate:2.02%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):139.17

Loading ...

Novartis Poised for Sales Growth Acceleration

Dow Jones
·
Sep 24

Lilly's Next-Gen Obesity Efforts Could Tip Scales Further in Its Favor, Citi Says

Reuters
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Health Canada Approves AbbVie’s Epkinly Combo for Relapsed or Refractory Follicular Lymphoma in Adults

Reuters
·
Sep 24

Epkinly® Receives Health Canada Approval for Adults with Follicular Lymphoma

THOMSON REUTERS
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

Novo Nordisk's new strategy hinges on something it cannot manufacture: investor confidence

Deep News
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Novartis AG Rises Wednesday, Outperforms Market

Dow Jones
·
Sep 24

Novo Nordisk A/S Series B Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Sep 24

Novo Nordisk says CagriSema delivers ‘superior’ weight loss in REIMAGINE 5 trial

TIPRANKS
·
Sep 23